
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 18, 2026, 4:15 PM ET
ProKidney promoted Farah Ali, M.D., M.S., to Chief Medical Officer to lead the clinical program for the pivotal Phase 3 PROACT 1 study of rilparencel.
Nasdaq: $PROKDated clinical and operating evidenceFinancing and capital structureExecution risk
PROK Stock Hub: ProKidney News, PROACT 1 and Kidney Funding
Rilparencel faces a pivotal kidney-function test in Q2 2027. ProKidney reported $141.9 million of cash, cash equivalents and marketable securities at September 30, still expected to fund operations into mid-2027, and its November presentation now expects PROACT 1 to enroll more than 500 patients, up from 470, with full enrollment in Q1 2027 and a BLA submission for accelerated approval in Q1 2028. Third-quarter results on November 12 showed a $51.8 million net loss before noncontrolling interest, and the 10-Q again states substantial doubt about going concern.
Full research report · PDF
ProKidney ($PROK), research updated November 13, 2026
22 pages. Rilparencel faces a pivotal kidney-function test in Q2 2027. ProKidney reported $141.9 million of cash, cash equivalents and marketable securities at September 30, still expected to fund operations into mid-2027, and its November presentation now expects PROACT 1 to enroll more than 500 patients, up from 470, with full enrollment in Q1 2027 and a BLA submission for accelerated approval in Q1 2028. Third-quarter results on November 12 showed a $51.8 million net loss before noncontrolling interest, and the 10-Q again states substantial doubt about going concern. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next company-guided clinical window
Q2 2027 · PROACT 1 eGFR-slope topline
The company guides the eGFR-slope topline for accelerated approval to Q2 2027, without an exact day; the efficacy analysis set is expected to include about 320 patients. Its November 2026 presentation adds full PROACT 1 enrollment in Q1 2027, with more than 500 patients expected, a BLA submission for accelerated approval in Q1 2028 and a potential accelerated approval and launch in the first half of 2029. Company presentation, November 9 · Q3 release, November 12
The November 12 third-quarter release reiterated the Q2 2027 topline, full enrollment of more than 500 patients in Q1 2027 and the confirmatory composite clinical-outcome readout in H2 2029. All are company guidance; rilparencel is investigational.
PROK stock at a glance
Chart analysis · JC
Technical chart analysis of $PROK with bull and bear scenarios on JC Just Charts.
Class A + Class B · Nov 12, 2026
302.382M
Q3 Form 10-Q cover: 209.633M Class A and 92.748M Class B. Not a diluted denominator.
Class B / paired units · Nov 12, 2026
92.748M
Exchangeable one-for-one into Class A; 93.396M on October 15
Cash + marketable securities · Sep 30, 2026
$141.9M
Q3 release and Form 10-Q; $181.6M at June 30, 2026
Nine-month operating cash use
$120.7M
Nine months ended September 30, 2026; Q3 net loss before noncontrolling interest $51.8M.
Accelerated-analysis cohort
~320
Expected efficacy analysis set; total enrollment now expected above 500, up from 470, complete in Q1 2027. Not an efficacy result.
PROACT 1 surrogate window
Q2 2027
Company guidance, no exact release date.
Funding runway
Into mid-2027
Management expectation restated November 12, 2026; going-concern warning repeated in the September 30 Form 10-Q.
Where ProKidney stands now
At September 30, 2026, ProKidney held $141.9 million in cash, cash equivalents and marketable securities, first disclosed in its November 9 Form 8-K and confirmed in the November 12 third-quarter release, down from $181.6 million at June 30. In the third quarter research and development expenses rose to $40.8 million from $26.8 million a year earlier, general and administrative expenses were $13.1 million and the net loss before noncontrolling interest was $51.8 million; nine-month operating cash use was $120.7 million. Management still expects current cash to support operating plans into mid-2027, close to the Q2 2027 pivotal readout and before the BLA submission planned for Q1 2028; the September 30 Form 10-Q again states substantial doubt about the company’s ability to continue as a going concern within one year. The accelerated-analysis cohort of about 320 patients is enrolled, and the company now expects to enroll more than 500 patients in total, up from 470, with full enrollment in Q1 2027. Positive data would still leave regulatory, manufacturing and launch work to fund. Q3 release · September 30 Form 10-Q · November 9 Form 8-K · November 2026 presentation · June 30 Form 10-Q
Operating evidence, financing and regulatory outcomes remain separate. A biopsy-based autologous therapy must demonstrate controlled efficacy and procedural safety. Funding needs, a going-concern warning, paired units and additional issuance affect per-share outcomes.
The constructive case
The roughly 320-patient accelerated-approval cohort is enrolled, the company reports FDA alignment on eGFR slope as the surrogate with a 1.5 mL/min/1.73m² per year threshold versus sham, and Kidney Week 2026 adds a pooled Phase 2 analysis and seven mechanism and manufacturing abstracts before the Q2 2027 topline. In a subgroup analysis shown in the November presentation, the 15 REGEN-007 Group 1 participants meeting key PROACT 1 entry criteria had an annual eGFR slope of −6.46 before and −0.95 mL/min/1.73m² after treatment (difference 5.51; p=0.005); it is an open-label, uncontrolled comparison with each patient’s own prior decline, not a randomized result.
The cautious case
The Phase 2 signal is open-label and measured against each patient’s own historical decline. Cash of $141.9M at September 30, 2026 is guided only into mid-2027, before the planned Q1 2028 BLA submission and under the going-concern warning repeated in the September 30 filing, with a new $200M at-the-market program with Jefferies made usable by a November 12, 2026 prospectus supplement (the earlier July 2025 sales agreement is being terminated effective November 23, 2026), and an expired founders’ lock-up behind the share supply.
Latest ProKidney news
Nov 18, 2026
ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
ProKidney Corp. announced the promotion of Farah Ali, M.D., M.S., to Chief Medical Officer. Dr. Ali will lead the clinical program as the company advances the pivotal Phase 3 PROACT 1 study of rilparencel. She previously served as Senior Vice President, Clinical Development at Immunovant.
Nov 12, 2026
ProKidney reports third quarter 2026 financial results and business highlights
ProKidney reported a net loss before noncontrolling interest of $51.8 million for the three months ended September 30, 2026, compared to $35.8 million in 2025. Cash, cash equivalents and marketable securities totaled $141.9 million at September 30, 2026, supporting operations into mid-2027. The company expects PROACT 1 eGFR slope topline results in Q2 2027 and full enrollment in Q1 2027 with over 500 patients.
Nov 11, 2026
ProKidney files prospectus for up to $200 million at-the-market stock offering
ProKidney filed a prospectus for an at-the-market offering of up to $200,000,000 of Class A common stock, sold through Jefferies LLC as sales agent. The shares trade on the Nasdaq Capital Market under the symbol PROK, with a last reported sale price of $1.13 per share on November 11, 2026. Jefferies is entitled to a commission rate of up to 3.0% of the gross sales price per share. The prospectus is dated November 12, 2026.
Nov 9, 2026
Patients with Advanced CKD Want More Time: ProKidney Presentation
ProKidney's November 2026 corporate presentation outlines rilparencel, a novel autologous cell therapy, for patients with advanced CKD. The Phase 3 PROACT 1 trial is expected to complete full enrollment in Q1 2027, anticipating over 500 patients, with topline surrogate endpoint results in Q2 2027. The company anticipates a BLA submission for accelerated approval in Q1 2028. Current cash is expected to support operating plans into mid-2027.
Nov 3, 2026
ProKidney CEO acquires 500,000 performance-based options, 25% vested
ProKidney's CEO acquired 500,000 performance-based options. According to the headline, 25% of the options have vested. Not confirmed by a company release or filing at the time of writing; to be verified.
Oct 30, 2026
Regulatory officer exchanges paired units for Class A shares
The Form 4 reports conversion of 200,000 paired Class B shares and common units into Class A shares on October 28. The filing shows 200,000 Class A shares and 202,283 paired units remaining; it does not report an open-market purchase.
PROK stock catalysts and dated operating windows
- November 12, 2026 — Third-quarter 2026 results: $141.9M of cash and securities at September 30, Q3 net loss before noncontrolling interest $51.8M, runway still guided into mid-2027. Completed · release and 10-Q
- November 23, 2026 — Termination of the July 2025 Jefferies sales agreement takes effect (notice delivered November 6). Disclosed in the Q3 Form 10-Q
- Q1 2027 — Full PROACT 1 enrollment, with more than 500 patients expected, up from 470. Company guidance
- Q2 2027 — PROACT 1 accelerated-cohort eGFR-slope topline; efficacy analysis set of about 320 patients. Company guidance, no fixed day
- Q1 2028 — BLA submission of rilparencel for accelerated approval. Company guidance
- H1 2029 — Potential accelerated approval and commercial launch. Company guidance, subject to FDA review
- H2 2029 — Confirmatory composite clinical-outcome analysis. Company guidance
- Into mid-2027 — Management funding outlook, restated November 12 with September 30 cash of $141.9M. Company expectation, not a cash measurement
Q3 2026 release · Q3 Form 10-Q · November 2026 presentation · November 9 Form 8-K · Primary source · Primary source
PROACT 1: the pivotal trial that decides the story
REGEN-006, also known as PROACT 1, is a randomized, blinded, sham-controlled Phase 3 study in patients with advanced CKD and type 2 diabetes. The study is being conducted in the United States, Mexico and Taiwan. Patients are randomized before kidney biopsy or sham biopsy, and the treatment group receives two injections three months apart, one into each kidney.
ProKidney has stated that PROACT 1 is designed with 90% power to detect an annualized eGFR-slope treatment effect of 1.75 mL/min/1.73m² and 80% power to detect an effect of 1.5 mL/min/1.73m². The company has also said the FDA considered a 1.5 effect versus sham acceptable in patients receiving appropriate standard of care.
Share classes, exchanges and actual dilution
At August 10 the cover of the 10-Q reports 208,926,941 Class A and 93,395,714 Class B shares. Class B shares pair with economic units in PK Holdings; the structure allows one-for-one exchange into Class A (or cash under the agreement). On October 15, 2026 the Form S-3 reports 208,975,486 Class A and 93,395,714 Class B shares. The company reported 209,633,391 Class A shares at November 12, 2026, and a combined 302,381,712-unit basis. The latter is an illustrative look-through equity basis, not the value of Class B voting shares on their own and not a fully diluted enterprise value. The same underlying units are not counted again. The November 2026 company presentation gives 302,381,712 Class A and Class B shares combined as of November 6, 2026; the cover of the September 30 Form 10-Q reports 209,633,391 Class A and 92,748,321 Class B shares at November 12, 2026, the same combined total.
On April 28 Control Empresarial exchanged 63,118,645 units and corresponding Class B shares into Class A. This explains most of the jump in listed A shares; it is an exchange of existing economic interests, not a cash raise creating the same amount of new combined ownership. Options, earnout conditions and later issuance require separate dilution treatment.
The Form S-3 filed on October 29, 2026 was declared effective on November 10, 2026, and on November 12 ProKidney filed the prospectus supplement for its Open Market Sale Agreement with Jefferies, which allows sales of Class A shares with an aggregate offering price of up to $200 million from time to time, at a commission of up to 3.0% of gross proceeds. As an illustration, the prospectus assumes the sale of 176,991,150 shares at $1.13, the last reported price on November 11, 2026, which would bring Class A shares to 382,707,339 on a June 30, 2026 basis; that block would equal about 58.5% of the 302,381,712 combined Class A and Class B shares of November 6 (Merlintrader arithmetic). Actual sales, prices and proceeds are not determinable and there is no assurance that any shares will be sold. The September 30 Form 10-Q states that no shares had been sold under the 2026 agreement as of its date and that on November 6, 2026 ProKidney gave Jefferies notice to terminate the July 2025 sales agreement, effective November 23, 2026; under that earlier program only 2,798 shares were sold in the first nine months of 2026, for $7,000 of net proceeds. Notice of effectiveness · Prospectus supplement · September 30 Form 10-Q
Merlintrader Health Score · $PROK
2.35out of 5
Assessed November 9, 2026, on the November 9 Form 8-K and presentation; reassessed November 12, 2026 after the shelf became effective and the prospectus supplement for the $200M Jefferies at-the-market program was filed: dilution lowered to 1.5 from 2.0, other scores unchanged; reviewed again November 12, 2026 after the third-quarter results and Form 10-Q (going-concern warning repeated, earlier ATM being terminated), with scores unchanged. Weighted calculation: 2.0×30% + 3.0×30% + 1.5×20% + 2.5×10% + 3.0×10% = 2.35. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Financial balances retain their reporting dates and currencies.
- Company guidance is not proof of completed execution or a regulatory decision.
- Financing obligations and additional shares can change per-share economics. The $200M at-the-market program with Jefferies became usable with the November 12, 2026 prospectus supplement; at the $1.13 reference price, the full amount would equal about 177 million new Class A shares. November 12 prospectus supplement
PROK Stock FAQ: ProKidney Questions Answered
When is the next PROK stock catalyst?
ProKidney guides PROACT 1 eGFR-slope topline from its roughly 320-patient efficacy analysis set to Q2 2027. Its November 9, 2026 presentation adds full enrollment of more than 500 patients in Q1 2027, a BLA submission for accelerated approval in Q1 2028, potential accelerated approval and launch in the first half of 2029 and the confirmatory composite clinical-outcome readout in H2 2029. None of these windows supplies an exact date. November 2026 milestones. Pivotal trial cohorts and reporting windows.
Is ProKidney’s rilparencel FDA approved?
No: ProKidney’s August 10, 2026 report describes investigational rilparencel in the Phase 3 PROACT 1 trial. The eGFR-slope cohort is intended to support a possible accelerated-approval application, while the broader trial follows clinical outcomes. Trial enrollment is complete for the accelerated analysis; efficacy has not yet been established by that result. Investigational status and accelerated-analysis plan.
How much cash does ProKidney have, and how long will it last?
ProKidney held $141.9 million in cash, cash equivalents and marketable securities at September 30, 2026, according to its November 12 third-quarter release, down from $181.6 million at June 30, and still expects current cash to support operating plans into mid-2027. Nine-month operating cash use was about $120.7 million, against a net loss of about $140.9 million. The September 30 quarterly filing again states substantial doubt about going concern, with additional funding needed beyond the current plan. September 30 cash and runway. Liquidity, operating cash use and going concern.
Is PROK stock at risk of dilution?
Yes: on November 12, 2026 ProKidney filed the prospectus supplement for a new at-the-market program with Jefferies for up to $200 million of Class A shares. $200M at-the-market prospectus. Trading history. At November 12, ProKidney had 209,633,391 Class A and 92,748,321 Class B shares outstanding, and paired Class B shares and units can exchange one-for-one into Class A. As of that date no shares had been sold under the new agreement, and the July 2025 program is being terminated effective November 23, 2026. ATM programs and November 12 share counts.
When does ProKidney report earnings?
ProKidney reported full third-quarter 2026 results on November 12, 2026, with its Form 10-Q, after disclosing September 30 cash of $141.9 million in a November 9 Form 8-K; as of November 12 the next results date had not been announced. The October 27 KOL event was a scientific and corporate update, not a results date. November 9 Form 8-K. Company investor information. Dated KOL event. Latest quarterly filing. Investor calendar.
What does ProKidney do?
ProKidney develops rilparencel, an investigational autologous cell therapy for advanced chronic kidney disease associated with type 2 diabetes. Cells originate from a patient’s own kidney biopsy and are delivered into both kidneys through injections approximately three months apart. The Phase 3 program tests whether treatment slows kidney-function loss. Therapy, procedure and development stage.
What did ProKidney have accepted at Kidney Week 2026?
ProKidney’s October 2, 2026 announcement listed eight abstracts for the October 21–25 meeting in Denver: an October 23 oral presentation in a rat CKD model, six non-clinical posters on mechanism and manufacturing, and one pooled Phase 2 analysis in participants meeting key Phase 3 criteria. That announcement gave no numerical results for the pooled clinical analysis. Accepted abstracts and their scope.
Did ProKidney’s October insider filing report a market purchase?
No: ProKidney’s October 30, 2026 Form 4 reports the chief regulatory officer’s October 28 exchange of 200,000 paired Class B shares and units for Class A shares. The disclosed transaction is a conversion, rather than an open-market purchase for cash. Insider transaction and explanatory footnotes.
Primary sources
- November 12, 2026 — Third-quarter 2026 results: $141.9 million of cash and securities, runway into mid-2027
- November 12, 2026 — Form 10-Q for the quarter ended September 30, 2026: going concern, ATM programs, share counts
- November 12, 2026 — Prospectus supplement: at-the-market program with Jefferies for up to $200 million of Class A shares, commission up to 3.0%
- November 10, 2026 — Notice of effectiveness of the Form S-3 shelf registration
- November 9, 2026 — Form 8-K: September 30 cash of $141.9 million
- November 9, 2026 — Corporate presentation: enrollment above 500, BLA planned for Q1 2028
- October 30, 2026 — Regulatory officer exchanges paired units for Class A shares
- October 29, 2026 — Shelf registration filed with a new $200M at-the-market sales agreement with Jefferies
- October 22, 2026 — Virtual KOL event on October 27 after ASN Kidney Week
- October 2, 2026 — Eight Kidney Week 2026 abstracts
- August 20, 2026 — Director sales filed
- August 10, 2026 — Accelerated cohort enrolled
- Historical financial and development basis
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $PROK or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



